# SECTION 8 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is K130141.

807.92 (a)(1): Name: Hitachi Chemical Diagnostics Address: 630 Clyde Court Mountain View, CA 94043

Phone: (650) 961 5501 FAX: (650) 969 2745 Contact: Mr. Charles Tsou

807.92 (a)(2): Device name- trade name and common name, and classification

Trade name: S TEST Reagent Cartridge Alkaline Phosphatase (ALP)

Common Name: Routine chemistry analyzer for ALP

Classifications: 21 CFR $\ S 8 6 2 . 1 0 5 0$ Alkaline Phosphatase (ALP)

807.92 (a)(3): Identification of the legally marketed predicate devices

Cobas c systems ALP2 (Roche Diagnostics, Inc., Indianapolis, IN)- K100853

# 807.92 (a)(4): Device Description

The Hitachi Clinical Analyzer is an automatic, bench-top, wet chemistry system intended for use in clinical laboratories or physician office laboratories. The instrument consists of a desktop analyzer unit, an operations screen that prompts the user for operation input and displays data, a printer, and a unit cover. The analyzer unit includes a single probe, an incubation rotor, carousels for sample cups and reagent cartridges, and a multi-wavelength photometer. The single-use reagent cartridges may be placed in any configuration on the carousel, allowing the user to develop any test panel where the reagent cartridges are available.

The S TEST reagent cartridges are made of plastic and include two small reservoirs capable of holding two separate reagents (R1 and R2), separated by a reaction cell/photometric cuvette. The cartridges also include a dot code label that contains all chemistry parameters, catcsanuio-elataion,expti atTe dimensions of the reagent cartridges are: $1 3 . 5 \ \mathrm { m m } \ \mathrm { ( W ) } \times 2 8 \ \mathrm { m m } \ \mathrm { ( D ) } \times 2 0 . 2 \ \mathrm { m m } \ \mathrm { ( H ) } .$ Y

System operation: After the sample cup is placed into the carousel, the analyzer pipettes the sample, pipettes the reagent, and mixes (stirs) the sample and reagent together. After the sample and reagent react in the incubator bath, the analyzer measures the absorbance of the sample, and based on the absorbance of the reactions, it calculates the concentration of analyte in the sample. The test system can measure analytes in serum or plasma and results are available in approximately 15 minutes per test. This submission is for Reagent Cartridge ALP.

Chemistry reactions:Alkaline phosphatase (ALP) in the sample reacts with its substrate, pnitrophenyl phosphate (p-NPP), in ethylaminoethanol (EAE) buffer, to release $\pmb { \mathsf p }$ -nitrophenol (yellow). The ALP activity is determined by measuring the rate of $\pmb { \mathsf { p } }$ nitrophenol production.

# 807.92 (a)(5): Intended Use

The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for the quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma using the HITACHI Clinical Analyzer. The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Meea a parathyroid, and intestinal diseases.

# Page 2 of 6

807.92 (a)(6): Technological Similarities and Differences to the Predicate The following chart describes similarities and differences between the two test system   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Hitachi S TEST Systems</td><td rowspan=1 colspan=1>PREDICATE</td></tr><tr><td rowspan=1 colspan=1>Instrument Platform</td><td rowspan=1 colspan=1>Hitachi Clinical Analyzer(originally cleared under K111753)</td><td rowspan=1 colspan=1>Roche cobas c systems  K100853</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Alkaline Phosphatase (ALP)</td><td rowspan=1 colspan=1>K number- pending</td><td rowspan=1 colspan=1>Roche K number- K100853</td></tr><tr><td rowspan=1 colspan=1>Device Class, Regulation Code</td><td rowspan=1 colspan=1>Class II, 21 CFR 862.1050</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Classification Product Code</td><td rowspan=1 colspan=1>CJE</td><td rowspan=1 colspan=1>CJE</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determination of ALP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Testing Environment</td><td rowspan=1 colspan=1>Physician office or clinical lab</td><td rowspan=1 colspan=1>Clinical lab</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>In the presence of magnesium ions,ALP reacts with p-NPP to release p-nitrophenol.</td><td rowspan=1 colspan=1>In the presence of magnesium andzinc ions, p-NPP is cleaved byphosphatases into phosphate and p-nitrophenol</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human serum or plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>10 to 1,000 U/L</td><td rowspan=1 colspan=1>5 to 1,200 U/L</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>405/508 nm</td><td rowspan=1 colspan=1>480/450 nm</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>5 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>5 to 1,000 U/L</td><td rowspan=1 colspan=1>5 to 1,200 U/L</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CVs range from 4.4% to 5.8%</td><td rowspan=1 colspan=1>%CVs range from 0.6% to 2.4%</td></tr></table>

# 807.92 (b)(1): Brief Description of Nonclinical Data

A series of studies were performed that evaluated the following nonclinical performance characteristics for each analyte: analytical sensitivity (limits of detection), linearity, 20-day in-house precision, interference testing, in-house method comparisons, and matrices comparison between serum and heparin plasma.

Analytical Sensitivity (Limits of Detection) The study followed CLSI EP17-A, and the limit of detection was found to be $1 . 8 \ : \mathrm { U } / \mathrm { L }$

The study followed CLSI EP-6A, and the range of linearity was $5 \mathrm { \textrm U } / \mathrm { L }$ to $^ { 1 , 0 0 0 } \mathrm { U } / \mathrm { L }$ .

20-day In-house Precision   
The studies followed CLSI EP5-A2, where three levels of samples were each tested in two   
runs, twice a day, for 20 days. The results were as follows:

ALP- Low, Level 1, Summary   

<table><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>42.7</td><td rowspan=1 colspan=1>42.7</td></tr><tr><td rowspan=1 colspan=1>SD (U/L)</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>2.25</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>F             3.1%</td><td rowspan=1 colspan=1>5.3%</td></tr></table>

ALP- Middle, Level 2, Summary   

<table><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>80.5</td><td rowspan=1 colspan=1>80.5</td></tr><tr><td rowspan=1 colspan=1>SD (U/L)</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>4.65</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>5.8%</td></tr></table>

ALP- High, Level 3, Summary   

<table><tr><td rowspan=1 colspan=1>ALP</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>555.6</td><td rowspan=1 colspan=1>555.6</td></tr><tr><td rowspan=1 colspan=1>SD (U/L)</td><td rowspan=1 colspan=1>13.99</td><td rowspan=1 colspan=1>24.69</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>4.4%</td></tr></table>

# Interference Testing (per CLSI EP7-A2)

The data demonstrated that the ALP test system was not affected by high levels of the following substances at the levels noted:

Hemoglobin: no interference up to $5 0 0 ~ \mathrm { m g / d L }$ Unconjugated bilirubin: no interference up to $5 0 ~ \mathrm { m g / d L }$ Lipemia: no interference up to $2 , 0 0 0 \mathrm { m g / d L }$ EY Ascorbic acid: no interference up to $5 0 \mathrm { m g / d L }$

Lack of interference was defined as recoveries between $90 \%$ and $1 1 0 \%$ of the neat value, and assay performance claims were established on the HITACHI Clinical Analyzer by testing two serum pools containing approximately $1 2 \ m \mathbf { g } / \mathbf { L }$ and $8 0 U / L$ ALP.

# Method Comparison

A total of 97 clinical specimens spanning the dynamic range (11 to $9 2 6 \mathrm { U } / \mathrm { L } )$ , were assayed in singleton and in a blinded fashion by both the Hitachi system and a standard laboratory system. The comparative data were analyzed by linear regression and are shown below. ( $\mathbf { \partial } \mathbf { C I } =$ confidence interval)

# ALP Regression Statistics:

Page 4 of 6   

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>y-intercept(95% CI)</td><td rowspan=1 colspan=1>X mean</td><td rowspan=1 colspan=1>Y mean</td></tr><tr><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.926(0.909 to 0.943)</td><td rowspan=1 colspan=1>4.8(-0.2 to 9.8)</td><td rowspan=1 colspan=1>203 U/L</td><td rowspan=1 colspan=1>193 U/L</td></tr></table>

$\circledcirc$ Hitachi Chemical Dlagnostics, Inc. 630 Clyde Court, Mountain View, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745

www.hcdiagnostics.com

# Matrices Comparisons

A study was performed to validate the use of two plasma types as an alternative to serum for the Hitachi Clinical Analyzer with S TEST Reagent Cartridge Alkaline Phosphatase (ALP). The plasma types were sodium citrate and lithium heparin. Thirty-eight (38) matched serum/plasma samples that spanned the dynamic range (13 to 967) were assayed in singleton and the results were compared using linear regression (plasma $=$ y-axis, each type). The performance characteristics were as follows.

$\aleph = 3 8$ Range (serum) $= 1 3$ to $9 6 7 \mathrm { U } / \mathrm { L }$   

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>Sodium Citrate Plasma</td><td rowspan=1 colspan=1>Heparinized Plasma</td></tr><tr><td rowspan=1 colspan=1>Slope (95% CIs)</td><td rowspan=1 colspan=1>1.03 (1.01 to 1.05)</td><td rowspan=1 colspan=1>1.01 (1.00 to 1.02)</td></tr><tr><td rowspan=1 colspan=1>y-intercept (95% Cls)</td><td rowspan=1 colspan=1>-11.2 (-15.5 to -7.0)</td><td rowspan=1 colspan=1>-5.4 (-8.3 to -2.6)</td></tr><tr><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.999</td></tr></table>

# 807.92 (b)(2): Brief Description of Clinical Data

Studies for precision and method comparison (accuracy) were performed at three external POL-type sites to evaluate the Hitachi Clinical Analyzer with S TEST Reagent Cartridges Alkaline Phosphatase (ALP) in one of its targeted intended use environments, the physician's office laboratory.

For the external site precision study, each site received three blinded serum samples (the Precision Panel, labeled A, B, and C) that were chosen to represent low, midle, and high concentrations of ALP. Each sample was assayed six times per day for five days, reporting 30 results per level. Precision estimates for total precision were as follows:

ALP (U/L) ${ \bf n } = { \bf 3 0 }$ replicates per sample per site   
Page 5 of 6   

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD (U/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>7.3%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>9.2%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Middle</td><td rowspan=1 colspan=1>76.2</td><td rowspan=1 colspan=1>2.26</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Middle</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>5.24</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>Middle</td><td rowspan=1 colspan=1>70.0</td><td rowspan=1 colspan=1>6.28</td><td rowspan=1 colspan=1>9.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>canma</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>408.6</td><td rowspan=1 colspan=1>26.01</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>390.1</td><td rowspan=1 colspan=1>23.21</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>402.9</td><td rowspan=1 colspan=1>12.33</td><td rowspan=1 colspan=1>3.1%</td></tr></table>

$\circledcirc$ Hitachl Chemical Diagnostics, Inc. 630 Clyde Court, Mountaln Vlew. CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745

For the external site method comparison study, a series of approximately 70 serum specimens with ALP values ranging from 11 to $7 4 5 ~ \mathrm { U } / \mathrm { L }$ were assayed on the Hitachi Clinical Analyzer at three sites using S TEST Reagent Cartridge Alkaline Phosphatase (ALP) (y) and a comparative method as the reference method (x). Linear regression analysis (least squares) yielded the following results:

POL ACCURACY DATA SUMMARY- ALP (U/L)   

<table><tr><td rowspan=1 colspan=1>Site #</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>HitachiRange</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>&quot;6p&quot;</td><td rowspan=1 colspan=1>95% CISlope</td><td rowspan=1 colspan=1>95% CIIntercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>13 to 745</td><td rowspan=1 colspan=1>y=0.967x +2.9</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.949 to 0.984</td><td rowspan=1 colspan=1>-0.6 to 6.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>11 to 688</td><td rowspan=1 colspan=1>y=0.942x -0.7</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.925 to 0.960</td><td rowspan=1 colspan=1>-4.4 to 2.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>12 to 736</td><td rowspan=1 colspan=1>y= 0.980x + 0.8</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.961 to 0.999</td><td rowspan=1 colspan=1>-3.2 to 4.7</td></tr></table>

# 807.92 (b)(3): Conclusions from Nonclinical and Clinical Testing

Nonclinical and clinical testing was performed for the Hitachi Clinical Analyzer with S TEST Reagent Cartridge Alkaline Phosphatase (ALP). The test system was shown to be safe and effective for its intended use.

# March 22, 2013

Hitachi Chemical Diagnostics, Inc. c/o Erika Ammirati   
630 Clyde Court   
Mountain View, CA 94043

Re: k130141 Trade/Device Name: S TEST Reagent Cartridge Alkaline Phosphatase (ALP) Regulation Number: 21 CFR $\ S 8 6 2 . 1 0 5 0$ EY Regulation Name: Alkaline Phosphatase or isoenzymes test system Regulatory Class: Class II Product Code: CJE Dated: January 18, 2013 Received: January 22, 2013

Dear Ms. Ammirati:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class â…¡I (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 1, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices   
Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): K130141

Device Name: S TEST Reagent Cartridge Alkaline Phosphatase (ALP)

# Indications for Use:

The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for the quantitative measurement of alkaline phosphatase activity in serum, lithium heparinized plasma, or sodium citrate plasma using the HITACHI Clinical Analyzer. The S TEST Reagent Cartridge Alkaline Phosphatase (ALP) is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Measurements of alkaline phosphatase are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Ruth A. Chesler -S

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health (OIR)

510(k) k130141